Author: Zacks Small Cap Research

1234513630 / 1351 POSTS
By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL RESEARCH REPORT Business Update Awaiting Data Readout of PRESECO Trial in COVID-19 In May 2021, Appili Therapeutics, Inc. (OTC:APLIF) (TSX:APLI.TO) announced that the independent Data Safety M ...
By Lisa Thompson OTC:PKKFF READ THE FULL PKKFF RESEARCH REPORT Peak Fintech (OTC:PKKFF) blew away our revenue estimate of $25 million coming in with a $30.6 million quarter, which was growth of 322% compared with last year. Taking out the bank intere ...
By Lisa Thompson NASDAQ:NETE READ THE FULL NETE RESEARCH REPORT Shareholders of Net Element (NASDAQ:NETE) have approved the merger with Mullen Technologies and we expect the deal to close shortly. A capital raise is the final condition for the merger ...
By M. Marin NASDAQ:VQS | TSX:VQS.V READ THE FULL VQS RESEARCH REPORT Backlog reached record levels… VIQ Solutions’ (NASDAQ:VQS) (TSX:VQS.V) backlog has reached record levels, reflecting growing demand from existing and new customers and some revenue ...
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Financial Update On August 17, 2021, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced financial results for the second quarter of 2021. The company reported $1.1 million in revenue ...
By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT LiFT Liver Biopsy Results On August 25th, 2021 Lipocine (NASDAQ:LPCN) released liver biopsy results for its Phase II LiFT study in NASH. LiFT, or Liver Fat Intervention with Ora ...
By M. Marin NASDAQ:ELYS READ THE FULL ELYS RESEARCH REPORT 1H21 Turnover up significantly Elys Game Technology (NASDAQ:ELYS) reported 2Q21 results last week. Year-to-date, the company has recorded record turnover – or betting handle – of $463.3 milli ...
By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Phase 3 DISRUPT Trial Continues ContraFect, Inc. (NASDAQ:CFRX) is currently conducting the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) tria ...
By Ann Heffron, CFA, CPA OTC:CPKF READ THE FULL CPKF RESEARCH REPORT CPKF’s (OTC:CPKF) second quarter net earnings jumped $1.9 million, or 93%, year over year to $4.0 million, while 2021’s second quarter diluted EPS soared by $0.40, or 96%, to $0.82 ...
By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT Business Update Phase 3 Program for Otenaproxesul on Pause On August 3, 2021, Antibe Therapeutics, Inc. (TSX:ATE.TO) (OTC:ATBPF) announced that the absorption, metabolism ...
1234513630 / 1351 POSTS